Catheter Precision Divests Non-Core Assets As It Shifts Focus
Catheter Precision (NYSE:VTAK) shares are down on Thursday as the company announced a strategic divestiture of its non-core assets.
VTAK Sells Atherectomy Catheter Tech to Focus on Electrophysiology
Catheter Precision on Thursday agreed to sell its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer.
This decision aims to enhance capital efficiency and sharpen the company’s focus on its high-growth electrophysiology platform.
The divestiture is expected to accelerate execution across its electrophysiology product portfolio while maintaining exposure to the future commercial success of the divested technologies. This strategic shift reflects the company’s commitment to advancing its core offerings in cardiac electrophysiology.
Transaction Highlights
Upfront cash payment following the closing of $15,000.
A 5% equity stake in the acquiring company with anti-dilution protection up to $5 million of additional equity capital being invested in the acquiring company.
Ten-year royalty payments agreement on net sales.
VTAK Stock Faces Bearish Trend Below SMA Levels
The stock is currently trading 21.1% below its 20-day simple moving average (SMA) and 31.7% below its 100-day SMA, indicating a bearish short-term trend.
Over the past 12 months, shares have decreased by 75.82% and are positioned closer to their 52-week lows than highs.
The RSI is at 44.39, which is considered neutral territory, while the MACD shows a value of -0.1249, below its signal line at -0.0886, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $2.00
- Key Support: $1.50
VTAK Price Action: Catheter Precision shares were down 5.05% at $1.61 at the time of publication on Thursday. The stock is near its 52-week low of $1.13.
Photo via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Despite falling oil prices and dovish comments from Fed officials, US Treasury yields continue to rise
The wave of US Treasury sell-offs continues to spread, with the 30-year yield reaching a 24-year high of 5.621% and the 10-year yield rising to its highest level since 2002—oil price declines and dovish signals have both failed, and long-term rates remain unaffected. High yields are reshaping the structure of US equities; as the AI narrative becomes the market’s final pillar, any cracks could trigger a chain reaction of turbulence.
Morgan Stanley trading desk, dubbed the "most accurate in the past two years," turns bullish
The supporting logic encompasses five major pillars: unexpected macro trends, consumer resilience, low profit expectations, stabilized yields, and technical improvements. Since the previous shift on August 31, the Nasdaq 100 long and Russell 2000 short paired trades have accumulated gains of over 8%. This latest "bullish reversal" is even more convincing. Strategically, technology remains the core long position, but the hedging tool has shifted from shorting RTY to derivatives. Meanwhile, the risk of long-term interest rate hikes still persists.
Four major favorable factors emerge, international oil prices respond by falling
Crypto prices
More
